On September 11, 2019 Zetagen Therapeutics, a private, US-based biopharmaceutical company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, reported its award of $225,000 USD from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH) (Press release, Zetagen Therapeutics, SEP 11, 2019, View Source [SID1234643689]). The grant will be used for a Phase I validation study of a novel, surgical implant for use with the Company’s small-molecule ZetaFuse. The implant is designed to repair damaged bone through stem cell activation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are extremely pleased to be recognized by the NIAMS, allowing us to enter our next phase of research," said Joe C. Loy, CEO of Zetagen Therapeutics, Inc. "This study further builds on our earlier validation studies, allowing us to now focus on how to successfully repair damaged bone by activating the body’s own stem cells – something which can potentially be applied beyond osteolytic cancers to other orthopedic interventions."

The NIAMS grant is part of the Small Business Innovation Research Program (SBIR), a three phase award system created by the Federal Government for small businesses to engage in research and development that has the potential for commercialization and public benefit. Zetagen exclusively-licensed its platform technology from the State University of New York in 2016.